You are here

Article Text

Article menu
Original article
MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma
Free
  1. Claudia Augello1,
  2. Umberto Gianelli2,
  3. Federica Savi3,
  4. Alessia Moro3,
  5. Emanuela Bonoldi4,
  6. Marcello Gambacorta5,
  7. Valentina Vaira6,
  8. Luca Baldini7,
  9. Silvano Bosari8
  1. 1Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
  2. 2Hematopathology Section, Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Ca’ Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy
  3. 3Division of Pathology, San Paolo Hospital, Milan, Italy
  4. 4Division of Pathology, A.Manzoni Hospital, Lecco, Italy
  5. 5Department of Laboratory Medicine, Niguarda Ca’ Granda Hospital, Milan, Italy
  6. 6Division of Pathology, IRCCS Ca’ Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy
  7. 7Division of Hematology, Department of Clinical and Community Sciences, University of Milan, IRCCS Ca’ Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy
  8. 8Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Ca’ Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy
  1. Correspondence to Dr Umberto Gianelli, Hematopathology Service, Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Ca’ Granda—Maggiore Policlinico Hospital Foundation, Via Francesco Sforza 35, Milano 20122, Italy; umberto.gianelli{at}unimi.it

Abstract

Aims To identify molecular characteristics to hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) through a comprehensive miRNAs expression profiling.

Methods In this study, miRNA profiles were obtained from 37 patients with DLBCLs and 60 patients with reactive lymph nodes, equally distributed according to HCV presence. Germinal centres, from reactive lymph nodes were used as controls. Clinical features at presentation were available for all patients.

Results A set of 52 miRNAs define a signature for HCV-associated DLBCL. Importantly, decreased expression of miR-138-5p and increased expression of miR-147a, miR-147b and miR-511-5p in HCV DLBCL was found to be a poor prognostic factor for HCV-positive DLBCL patients.

Conclusions These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers.

  • LYMPHOMA
  • VIRUS
  • HEPATITIS

https://doi.org/10.1136/jclinpath-2014-202352

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

      Files in this Data Supplement:

    • Abstract in Italian

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

      Files in this Data Supplement: